vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v12i6.887vsp-269Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCLINICAL OBSERVATIONSОПЫТ ПРИМЕНЕНИЯ АДАЛИМУМАБА У БОЛЬНОГО С СИСТЕМНЫМ ЮВЕНИЛЬНЫМ ИДИОПАТИЧЕСКИМ АРТРИТОМADALIMUMAB IN TREATMENT OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITISДенисоваР. В.DenisovaR. V.alekatya@ya.ruАлексееваЕ. И.AlexeevaE. I.alekatya@ya.ruИсаеваК. Б.IsaevaK. B.alekatya@ya.ruСлепцоваТ. В.SleptsovaT. V.alekatya@ya.ruБзароваТ. М.BzarovaT. M.alekatya@ya.ruВалиеваС. И.ValievaS. I.alekatya@ya.ruМитенкоЕ. В.MitenkoE. V.alekatya@ya.ruЧистяковаЕ. Г.ChistyakovaE. G.alekatya@ya.ruЧомахидзеА. М.ChomakhidzeA. M.alekatya@ya.ruФетисоваА. Н.FetisovaA. N.alekatya@ya.ruЛомакинаО. Л.LomakinaO. L.alekatya@ya.ruНаучный центр здоровья детей РАМН, МоскваРоссияScientific Centre of Children Health of RAMS, MoscowRussian FederationНаучный центр здоровья детей РАМН, Москва,; Первый Московский государственный медицинский университет им. И.М. СеченоваРоссияScientific Centre of Children Health of RAMS, Moscow; I.M. Sechenov First Moscow State Medical University,Russian FederationНаучный центр здоровья детей РАМН, МоскваРоссияScientific Centre of Children Health of RAMS, Moscow,Russian FederationНаучный центр здоровья детей РАМН, Москва; Первый Московский государственный медицинский университет им. И.М. СеченоваРоссияScientific Centre of Children Health of RAMS, Moscow; I.M. Sechenov First Moscow State Medical UniversityRussian Federation201307122013126Вопросы современной педиатрии123129Copyright © Денисова Р.В., Алексеева Е.И., Исаева К.Б., Слепцова Т.В., Бзарова Т.М., Валиева С.И., Митенко Е.В., Чистякова Е.Г., Чомахидзе А.М., Фетисова А.Н., Ломакина О.Л., 20132013Денисова Р.В., Алексеева Е.И., Исаева К.Б., Слепцова Т.В., Бзарова Т.М., Валиева С.И., Митенко Е.В., Чистякова Е.Г., Чомахидзе А.М., Фетисова А.Н., Ломакина О.Л.Denisova R.V., Alexeeva E.I., Isaeva K.B., Sleptsova T.V., Bzarova T.M., Valieva S.I., Mitenko E.V., Chistyakova E.G., Chomakhidze A.M., Fetisova A.N., Lomakina O.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/269

Представлен случай раннего дебюта и тяжелого течения системного ювенильного идиопатического артрита, рефрактерного к терапии классическими иммунодепрессантами. Приведенный клинический пример демонстрирует высокую терапевтическую эффективность адалимумаба у пациента с тяжелым течением системного ювенильного идиопатического артрита, длительной ремиссией внесуставных проявлений и персистирующим полиартритом. К 4-й нед терапии у пациента купировались воспалительные изменения в суставах, нарос объем движений, нормализовались лабораторные показатели активности болезни, была зарегистрирована стадия неактивной болезни. Длительность ремиссии суставного синдрома составила 2 года, обострения внесуставных проявлений за весь период наблюдения не зарегистрировано.

A history case of systemic juvenile idiopathic arthritis with early onset and severe clinical case, resistant to treatment with standard immunosuppressive agents is represented in the article. This case demonstrates high clinical efficacy of adalimumab in a patient with severe course of systemic juvenile idiopathic arthritis, prolonged remission of extra-articular involvement and persistent polyarthritis. By the 4th week of the treatment inflammatory changes in the joints had arrested, range of motions had widened, laboratory markers of activity had normalized and non-active stage of the disease had been established. The duration of the remission of articular syndrome was 2 years, no relapses were observed during the follow-up period.

детисистемный ювенильный идиопатический артритадалимумабchildrensystemic juvenile idiopathic arthritisadalimumabReferencesTexbook of paediatric rheumatology. 6th Ed. J. Cassidy, R. Petty (eds.). Philadelphia: Saunders Elsevier. 2011.Texbook of paediatric rheumatology. 6th Ed. J. Cassidy, R. Petty (eds.). Philadelphia: Saunders Elsevier. 2011.Singh-Grewal D., Schneider R., Bayer N., Feldman B. M. Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features. Arthritis Rheum. 2006; 54: 1595–1601.Singh-Grewal D., Schneider R., Bayer N., Feldman B. M. Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features. Arthritis Rheum. 2006; 54: 1595–1601.Lomater C., Gerloni V., Gattinara M., Mazzotti J., Cimaz R., Fantini F. Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J. Rheumatol. 2000; 27: 491–496.Lomater C., Gerloni V., Gattinara M., Mazzotti J., Cimaz R., Fantini F. Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J. Rheumatol. 2000; 27: 491–496.Spiegel L. R., Schneider R., Lang B. A., Birdi N., Silverman E. D., Laxer R. M. et al. Early predictors of poor functional outcome in systemiconset juvenile rheumatoid arthritis: a multicenter cohort study. Arthritis Rheum. 2000; 43: 2402–2409.Spiegel L. R., Schneider R., Lang B. A., Birdi N., Silverman E. D., Laxer R. M. et al. Early predictors of poor functional outcome in systemiconset juvenile rheumatoid arthritis: a multicenter cohort study. Arthritis Rheum. 2000; 43: 2402–2409.Petty R. E., Southwood T. R., Manners P., Baum J., Glass D. N., Goldenberg J. et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J. Rheumatol. 2004; 31: 390–392.Petty R. E., Southwood T. R., Manners P., Baum J., Glass D. N., Goldenberg J. et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J. Rheumatol. 2004; 31: 390–392.Bzarova T.M., Alekseeva E. I., Peterkova V. A. Rol faktorov bolezni i faktorov protivorevmaticheskoy terapii v razvitii nizkoroslosti u detey, stradayushchikh yuvenilnym revmatoidnym artritom [The role of disease and antirheumatic therapy factors in the development of dwarfism in children with juvenile rheumatoid arthritis]. Voprosy sovremennoy pediatrii — Current Pediatrics. 2006; 5 (5): 13–18.Bzarova T.M., Alekseeva E. I., Peterkova V. A. Rol faktorov bolezni i faktorov protivorevmaticheskoy terapii v razvitii nizkoroslosti u detey, stradayushchikh yuvenilnym revmatoidnym artritom [The role of disease and antirheumatic therapy factors in the development of dwarfism in children with juvenile rheumatoid arthritis]. Voprosy sovremennoy pediatrii — Current Pediatrics. 2006; 5 (5): 13–18.Ringold S, Weiss F. P., Beukelman T., DeWitt E. M., Ilowite N. T., Kimura Y., Laxer R. M., Lovell D. J., Nigrovic P. A., Robinson A. B., Vehe R. K. 2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis. Arthritis & Rheumatism. 2013; 65 (10): 2499–2512.Ringold S, Weiss F. P., Beukelman T., DeWitt E. M., Ilowite N. T., Kimura Y., Laxer R. M., Lovell D. J., Nigrovic P. A., Robinson A. B., Vehe R. K. 2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis. Arthritis & Rheumatism. 2013; 65 (10): 2499–2512.Alekseeva E. I., Valieva S. I., Apaeva D. V., Bzarova T. M., Isaeva K. B. Effektivnost puls-terapii metotreksatom s tsiklosporinom pri tyazhelom sistemnom variante yuvenilnogo revmatoidnogo artrita [The effectiveness of methotrexate pulse therapy with cyclosporine in severe systemic form of juvenile rheumatoid arthritis]. Voprosy sovremennoy pediatrii — Current Pediatrics. 2008; 7 (1): 29–34.Alekseeva E. I., Valieva S. I., Apaeva D. V., Bzarova T. M., Isaeva K. B. Effektivnost puls-terapii metotreksatom s tsiklosporinom pri tyazhelom sistemnom variante yuvenilnogo revmatoidnogo artrita [The effectiveness of methotrexate pulse therapy with cyclosporine in severe systemic form of juvenile rheumatoid arthritis]. Voprosy sovremennoy pediatrii — Current Pediatrics. 2008; 7 (1): 29–34.Beukelman T., Patkar N. M., Saag K. G., Tolleson-Rinehart S., Cron R. Q., DeWitt E. M. et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. (Hoboken). 2011; 63: 465–482.Beukelman T., Patkar N. M., Saag K. G., Tolleson-Rinehart S., Cron R. Q., DeWitt E. M. et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. (Hoboken). 2011; 63: 465–482.Alekseeva E. I., Alekseeva A. M., Valieva S. I., Bzarova T. M., Denisova R. V. Vliyaniye infliksimaba na klinicheskiye i laboratornye pokazateli aktivnosti pri razlichnykh variantakh yunosheskogo artrita [The effect of infliximab on the clinical and laboratory indicators of activity in different variants of juvenile arthritis]. Voprosy sovremennoy pediatrii — Current Pediatrics. 2008; 7 (2): 42–54.Alekseeva E. I., Alekseeva A. M., Valieva S. I., Bzarova T. M., Denisova R. V. Vliyaniye infliksimaba na klinicheskiye i laboratornye pokazateli aktivnosti pri razlichnykh variantakh yunosheskogo artrita [The effect of infliximab on the clinical and laboratory indicators of activity in different variants of juvenile arthritis]. Voprosy sovremennoy pediatrii — Current Pediatrics. 2008; 7 (2): 42–54.Alexeeva E. I., Valieva S. I., Bzarova T. M., Semikina E. L., Isaeva K. B., Lisitsyn A. O., Denisova R. V., Chistyakova E. G. Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. Clin. Rheumatol. 2011; 30 (9): 1163–1172.Alexeeva E. I., Valieva S. I., Bzarova T. M., Semikina E. L., Isaeva K. B., Lisitsyn A. O., Denisova R. V., Chistyakova E. G. Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. Clin. Rheumatol. 2011; 30 (9): 1163–1172.Feldman M., Brennan P., Maini R. Role of cytokines in rheumatoid arthritis. Ann. Rev. Immunol. 1996; 14: 397–440.Feldman M., Brennan P., Maini R. Role of cytokines in rheumatoid arthritis. Ann. Rev. Immunol. 1996; 14: 397–440.Beutler B. The role of tumor necrosis factor in health and disease. J. Rheumatol. 1999; 26 (Suppl. 57): 16–21.Beutler B. The role of tumor necrosis factor in health and disease. J. Rheumatol. 1999; 26 (Suppl. 57): 16–21.Aikawa E. N., de Carvalho J. F., Silva A. A. C., Bonfa E. Immunogenicity of anti-TNF- agents in autoimmune diseases. Clin. Rev. Allerg. Immunol. 2010; 38 (2–3): 82–89.Aikawa E. N., de Carvalho J. F., Silva A. A. C., Bonfa E. Immunogenicity of anti-TNF- agents in autoimmune diseases. Clin. Rev. Allerg. Immunol. 2010; 38 (2–3): 82–89.Weinblatt M. E., Keystone E. C., Furst D. E., Moreland L. W., Weisman M. H., Birbara C. A. et al. Adalimumab, a fully human antitumor necrosis factor-alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum. 2003; 48: 35–45.Weinblatt M. E., Keystone E. C., Furst D. E., Moreland L. W., Weisman M. H., Birbara C. A. et al. Adalimumab, a fully human antitumor necrosis factor-alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum. 2003; 48: 35–45.Breedveld F. C., Weisman M. H., Kavanaugh A. F., Cohen S. B., Pavelka K., van Vollenhoven R. et al. The PREMIER study: A multicenter, randomized, double blind clinical trial of combination therapy with Adalimumab plus methotrexate versus methotrexate alone or Adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006; 54: 26–37.Breedveld F. C., Weisman M. H., Kavanaugh A. F., Cohen S. B., Pavelka K., van Vollenhoven R. et al. The PREMIER study: A multicenter, randomized, double blind clinical trial of combination therapy with Adalimumab plus methotrexate versus methotrexate alone or Adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006; 54: 26–37.Burmester G. R., Manette X. Montecucco C. M., Monteagudo-Saez I., Malaise M., Tzioufas A. G. et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: The Research in Active Rheumatoid Arthritis (ReAct) trial. Ann. Rheum. Dis. 2007; 66 (6): 732–739.Burmester G. R., Manette X. Montecucco C. M., Monteagudo-Saez I., Malaise M., Tzioufas A. G. et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: The Research in Active Rheumatoid Arthritis (ReAct) trial. Ann. Rheum. Dis. 2007; 66 (6): 732–739.Nicas S. N., Voulgan P. V., Alamanos Y., Papadopoulos C. G., Venetsanopoulou A. I., Georgiadis A. N. et al. Efficacy and safety of switching from infliximab to adalimumab: A comparative controlled study. Ann. Rheum. Dis. 2006; 65: 257–260.Nicas S. N., Voulgan P. V., Alamanos Y., Papadopoulos C. G., Venetsanopoulou A. I., Georgiadis A. N. et al. Efficacy and safety of switching from infliximab to adalimumab: A comparative controlled study. Ann. Rheum. Dis. 2006; 65: 257–260.Haibel H., Rudwaleit M., Listing J., Heldmann F., Wong R. L., Kupper H. et al. Efficacy of Adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: Results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum. 2008; 58 (7): 1981–1991.Haibel H., Rudwaleit M., Listing J., Heldmann F., Wong R. L., Kupper H. et al. Efficacy of Adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: Results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum. 2008; 58 (7): 1981–1991.Lovell D., Ruperto N., Reiff A., Jung L. K., Higgins G., KonePaut I., Jones Olcay Y., McIlraith M. J., Andhivarothai N., Kupper H., Giannini E. H., Peterson T., Martini A. Long-term efficacy and safety of adalimumab for up to 6 years in patients with juvenile idiopathic arthritis. Abstract presented at: 75th Annual scientific meeting of the American College of Rheumatology (ACR) and the 46th Annual meeting of the Association of Rheumatology Health Professionals (ARHP). Chicago, IL. USA. 2011. Abstract MIS (7190791).Lovell D., Ruperto N., Reiff A., Jung L. K., Higgins G., KonePaut I., Jones Olcay Y., McIlraith M. J., Andhivarothai N., Kupper H., Giannini E. H., Peterson T., Martini A. Long-term efficacy and safety of adalimumab for up to 6 years in patients with juvenile idiopathic arthritis. Abstract presented at: 75th Annual scientific meeting of the American College of Rheumatology (ACR) and the 46th Annual meeting of the Association of Rheumatology Health Professionals (ARHP). Chicago, IL. USA. 2011. Abstract MIS (7190791).Lovell D. J., Ruperto N., Reiff A., Jung L. K., Higgins G., KonePaut I. et al. OLE DE 038: Long-term efficacy and safety of ADA for up to 6 years in patients with JIA. ACR11. Arthritis Rheum. 2011; 63 (10; Suppl.): abstract 265.Lovell D. J., Ruperto N., Reiff A., Jung L. K., Higgins G., KonePaut I. et al. OLE DE 038: Long-term efficacy and safety of ADA for up to 6 years in patients with JIA. ACR11. Arthritis Rheum. 2011; 63 (10; Suppl.): abstract 265.Breda L., Del Torto M., De Sanctis S., Chiarelli F. Biologics in children’s autoimmune disorders: Efficacy and safety. Eur. J. Pediatr. 2011; 170: 157–167.Breda L., Del Torto M., De Sanctis S., Chiarelli F. Biologics in children’s autoimmune disorders: Efficacy and safety. Eur. J. Pediatr. 2011; 170: 157–167.Ruperto N., Lovell D. J., Reiff A., Gamir M., Higgins G., KonePaut I. et al. Long-term efficacy and safety of Adalimumab in 4–12 year old patients with juvenile idiopathic arthritis. Pediatr. Rheumatol. 2011; 9 (Suppl. 1): 26.Ruperto N., Lovell D. J., Reiff A., Gamir M., Higgins G., KonePaut I. et al. Long-term efficacy and safety of Adalimumab in 4–12 year old patients with juvenile idiopathic arthritis. Pediatr. Rheumatol. 2011; 9 (Suppl. 1): 26.Lovell D. J., Ruperto N., Goodman S., Reiff A., Jung L., Jarosova K. et al. Adalimumab with or without Methotrexate in juvenile rheumatoid arthritis. N. Engl. J. Med. 2008; 359: 810–820.Lovell D. J., Ruperto N., Goodman S., Reiff A., Jung L., Jarosova K. et al. Adalimumab with or without Methotrexate in juvenile rheumatoid arthritis. N. Engl. J. Med. 2008; 359: 810–820.Beukelman T., Ringold S., Davis T. E., DeWitt E. M., Pelajo C. F., Weiss P. F., Kimura Y. Disease modifying anti-rheumatic drug use in the treatment of juvenile idiopathic arthritis: A cross-sectional analysis of the CARRA Registry. J. Rheumatol. 2012; 39 (9): 1867–1874.Beukelman T., Ringold S., Davis T. E., DeWitt E. M., Pelajo C. F., Weiss P. F., Kimura Y. Disease modifying anti-rheumatic drug use in the treatment of juvenile idiopathic arthritis: A cross-sectional analysis of the CARRA Registry. J. Rheumatol. 2012; 39 (9): 1867–1874.Trachana M., Pratsidou-Gertsi P., Pardalos G. Kozeis N., Badouraki M., Kanakoudi-Tsakalidou F. Safety and efficacy of adalimumab treatment in Greek children with juvenile idiopathic arthritis. Scand. J. Rheumatol. 2011; 40: 101–107.Trachana M., Pratsidou-Gertsi P., Pardalos G. Kozeis N., Badouraki M., Kanakoudi-Tsakalidou F. Safety and efficacy of adalimumab treatment in Greek children with juvenile idiopathic arthritis. Scand. J. Rheumatol. 2011; 40: 101–107.Russo R. A., Katsicas M. M. Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents. J. Rheumatol. 2009; 36 (5): 1078–1082.Russo R. A., Katsicas M. M. Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents. J. Rheumatol. 2009; 36 (5): 1078–1082.Alekseeva E. I., Bzarova T. M., Valieva S. I., Denisova R. V., Isaeva K. B., Chomakhidze A. M., Chistyakova E. G., Sleptsova T. V., Mitenko E. V., Taybulatov N. I. Effektivnost i bezopasnost chelovecheskikh monoklonalnykh antitel k FNO u detey s yuvenilnym idiopaticheskim artritom pri pervichnoy i vtorichnoy neeffektivnosti drugikh genno-inzhenernykh biologicheskikh preparatov [Efficacy and safety of human monoclonal antibodies to TNF in children with juvenile idiopathic arthritis in primary and secondary ineffectiveness of other genetically engineered biological agents]. Voprosy sovremennoy pediatrii — Current Pediatrics. 2012; 11 (4): 82–88.Alekseeva E. I., Bzarova T. M., Valieva S. I., Denisova R. V., Isaeva K. B., Chomakhidze A. M., Chistyakova E. G., Sleptsova T. V., Mitenko E. V., Taybulatov N. I. Effektivnost i bezopasnost chelovecheskikh monoklonalnykh antitel k FNO u detey s yuvenilnym idiopaticheskim artritom pri pervichnoy i vtorichnoy neeffektivnosti drugikh genno-inzhenernykh biologicheskikh preparatov [Efficacy and safety of human monoclonal antibodies to TNF in children with juvenile idiopathic arthritis in primary and secondary ineffectiveness of other genetically engineered biological agents]. Voprosy sovremennoy pediatrii — Current Pediatrics. 2012; 11 (4): 82–88.

The authors declare that there are no conflicts of interest present.